The Global Nintedanib API Market was valued at USD 112.6 Million in 2024 and is projected to reach USD 185.3 Million by 2030, growing at a Compound Annual Growth Rate (CAGR) of 7.8% during the forecast period (2024–2030). This significant growth is primarily driven by the increasing global prevalence of Idiopathic Pulmonary Fibrosis (IPF), expanded therapeutic applications for other interstitial lung diseases, and robust patent expiry strategies fostering generic competition.

As the pharmaceutical industry pivots toward advanced, targeted therapies, the production of high-quality Active Pharmaceutical Ingredients (APIs) like Nintedanib is critical. These companies are the backbone of the supply chain, ensuring the availability of life-saving medications. In this blog, we profile the Top 10 Companies in the Nintedanib API Industry—a mix of innovators, leading generic manufacturers, and specialized synthesis experts shaping the future of pulmonary fibrosis treatment.

---

🔟 1. Boehringer Ingelheim International GmbH

Headquarters: Ingelheim am Rhein, Germany
Key Offering: Nintedanib Esylate (Ofev® API)

Boehringer Ingelheim is the originator and patent holder of Nintedanib, marketed as Ofev®. The company maintains stringent control over its API synthesis for its proprietary drug product, which is approved for IPF and other progressive fibrosing ILDs. Their deep expertise in tyrosine kinase inhibition is foundational to the drug’s mechanism of action.

Innovation and Development Initiatives:

• Continuous process optimization for API manufacturing

• Ongoing clinical research for new therapeutic indications

• Commitment to sustainable and efficient manufacturing practices

Download FREE Sample Report: Nintedanib API Market – View in Detailed Research Report

---

9️⃣ 2. Teva Pharmaceutical Industries Ltd.

Headquarters: Tel Aviv, Israel
Key Offering: Generic Nintedanib API

As one of the world’s largest generic drug manufacturers, Teva is a dominant force in the post-patent API landscape. The company has robust capabilities in complex small molecule synthesis and is strategically positioned to supply high-volume, cost-effective Nintedanib API to generic drug manufacturers globally upon patent expiration.

Strategic Initiatives:

• Aggressive development of generic API portfolios

• Investment in scaling manufacturing capacity for high-demand APIs

• Global supply chain optimization for active ingredients

---

8️⃣ 3. Dr. Reddy’s Laboratories Ltd.

Headquarters: Hyderabad, India
Key Offering: Nintedanib Esylate API

Dr. Reddy’s is a key global player with a strong focus on developing and manufacturing complex APIs. The company’s vertically integrated operations and significant R&D investments make it a formidable competitor in the generic Nintedanib API space, particularly for markets in Asia and emerging economies.

Strategic Initiatives:

• Focus on developing non-infringing synthesis routes

• Expansion of regulatory filings in key international markets

• Commitment to high-quality, ICH-compliant manufacturing standards

---

7️⃣ 4. Sunshine Pharmaceutical Co., Ltd.

Headquarters: Shijiazhuang, China
Key Offering: Nintedanib API (Purity ≥98%, ≥99%)

Sunshine Pharmaceutical is a major Chinese manufacturer with a strong export-oriented API business. The company produces Nintedanib API in various purity grades to cater to both formulation development and commercial-scale production needs, serving a growing domestic and international client base.

Key Strengths:

• Competitive cost structure for API production

• Flexible manufacturing capabilities for custom purity specifications

• Strong foothold in the Asia-Pacific API supply chain

---

6️⃣ 5. Fermion Oy

Headquarters: Helsinki, Finland
Key Offering: High-Purity Nintedanib API

Fermion, a part of the Orion Corporation, specializes in the development and manufacture of active pharmaceutical ingredients for the global market. The company is known for its expertise in complex organic synthesis and produces high-purity Nintedanib API for pharmaceutical clients, with a focus on quality and regulatory compliance.

Key Strengths:

• Expertise in demanding chemical synthesis processes

• Strong regulatory track record with major agencies (EMA, FDA)

• Commitment to environmentally sustainable manufacturing

Download FREE Sample Report: Nintedanib API Market – View in Detailed Research Report

---

5️⃣ 6. Tecoland Corp.

Headquarters: Edison, New Jersey, USA
Key Offering: Nintedanib and Nintedanib Esylate

Tecoland is a specialized supplier of reference standards, intermediates, and APIs for the pharmaceutical and research industries. The company provides high-quality Nintedanib materials to support drug development, bioequivalence studies, and academic research, playing a crucial role in the pre-commercial and analytical testing ecosystem.

Key Strengths:

• Rapid supply of high-purity materials for R&D

• Specialization in complex molecules and patented drugs

• Support for analytical method development and validation

---

4️⃣ 7. Enantiotech Srl

Headquarters: Bologna, Italy
Key Offering: Nintedanib API and Key Intermediates

Enantiotech is an Italian CDMO (Contract Development and Manufacturing Organization) with expertise in chiral chemistry and the synthesis of complex APIs. The company offers Nintedanib API and its critical intermediates, providing valuable services for companies seeking to develop alternative, cost-effective synthesis pathways.

Key Strengths:

• Specialization in stereoselective synthesis

• Custom synthesis and process development services

• Strategic European location with access to key markets

---

3️⃣ 8. Guoding Pharmaceutical Co., Ltd.

Headquarters: Taizhou, China
Key Offering: Nintedanib Esylate API

Guoding Pharmaceutical is an established Chinese API manufacturer with a growing portfolio of oncology and specialty drug ingredients. The company has developed a robust manufacturing process for Nintedanib Esylate, positioning itself as a reliable supplier for generic pharmaceutical companies preparing for market entry.

Key Strengths:

• Integrated manufacturing from raw materials to finished API

• Cost-competitive production capabilities

• Active pursuit of regulatory approvals in strategic markets

---

2️⃣ 9. Haiwo Biological Technology Co., Ltd.

Headquarters: Shanghai, China
Key Offering: Nintedanib (Free Base and Esylate Salt)

Haiwo is a technology-driven company focused on the research, development, and production of advanced pharmaceutical intermediates and APIs. It supplies Nintedanib in both free base and esylate salt forms, offering flexibility to formulation developers and serving the research community with high-purity materials.

Key Strengths:

• Strong R&D capabilities for process innovation

• Ability to supply multiple chemical forms of the API

• Focus on serving both commercial and research segments

---

1️⃣ 10. Beijing Cooperate Pharmaceutical Co., Ltd.

Headquarters: Beijing, China
Key Offering: Nintedanib API

Beijing Cooperate Pharmaceutical is a specialized manufacturer of APIs and intermediates. The company has established itself as a supplier of Nintedanib API, leveraging China’s chemical manufacturing infrastructure to produce the compound efficiently while adhering to international quality standards required by global pharmaceutical partners.

Key Strengths:

• Established track record in API manufacturing

• Strategic partnerships with international pharmaceutical companies

• Focus on scalability and supply chain reliability

Get Full Report Here: Nintedanib API Market – View in Detailed Research Report

---

🌍 Outlook: The Future of Nintedanib API Is Defined by Genericization and Innovation

The Nintedanib API market is at a pivotal juncture. While the originator product continues to drive significant revenue, the impending patent cliff is set to catalyze a dynamic shift toward generic competition. This transition will be characterized by intense competition on price, a emphasis on manufacturing efficiency, and continued exploration of the drug’s therapeutic potential.

📈 Key Trends Shaping the Market:

• Patent Expiry Dynamics: Key composition of matter patents for Nintedanib are expected to expire in major markets post-2025, opening the floodgates for generic API manufacturers.

• Expanding Therapeutic Indications: Ongoing clinical trials for new indications beyond IPF, such as other fibrotic diseases, could significantly expand the addressable patient population and API demand.

• Geographical Market Growth: Rising diagnosis rates and improving healthcare access in emerging economies, particularly in Asia-Pacific, are creating new growth vectors for API suppliers.

• Supply Chain Resilience: Pharmaceutical companies are diversifying their API sourcing strategies, favoring manufacturers with proven quality systems and reliable supply chains to mitigate geopolitical and logistical risks.

Get Full Report Here: Nintedanib API Market – View in Detailed Research Report

The companies listed above are not only supplying a critical therapeutic ingredient—they are enabling greater patient access to a life-changing treatment for pulmonary fibrosis. Their expertise in complex chemistry and regulatory compliance ensures that the promise of this important medicine can be realized on a global scale.